These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 30024924

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
    Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, Mitnick CD, Rich ML, Islam S, Zhizhilashvili D, Yeghiazaryan L, Nikolenko EN, Zarli K, Adnan S, Salahuddin N, Ahmed S, Vargas ZHR, Bekele A, Shaimerdenova A, Tamirat M, Gelin A, Vilbrun SC, Hewison C, Khan U, Franke M.
    Nat Commun; 2024 May 09; 15(1):3927. PubMed ID: 38724531
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
    Udwadia ZF, Amale RA, Mullerpattan JB.
    Int J Tuberc Lung Dis; 2014 Nov 09; 18(11):1315-8. PubMed ID: 25299863
    [Abstract] [Full Text] [Related]

  • 27. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, Hafkin J.
    Trials; 2024 Jan 19; 25(1):70. PubMed ID: 38243296
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J, Reljic T, Kumar A.
    Indian J Pharmacol; 2016 Jan 19; 48(2):186-91. PubMed ID: 27127322
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R, Singla N, Vohra V, Singla R, Puri MM, Munjal S, Khalid UK, Myneedu VP, Kumar Verma A, Mathuria KK.
    Indian J Tuberc; 2019 Jan 19; 66(1):209-213. PubMed ID: 30878071
    [Abstract] [Full Text] [Related]

  • 32. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country.
    Ige OM, Oladokun RE.
    Indian J Tuberc; 2018 Oct 19; 65(4):322-328. PubMed ID: 30522620
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S.
    Clin Infect Dis; 2019 Apr 24; 68(9):1522-1529. PubMed ID: 30165431
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.